Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study-Reference-Cited by-同舟云学术

Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study

Published:2023-01 Issue: Volume:106 Page:105238
ISSN:1353-8020
Container-title:Parkinsonism & Related Disorders
language:en
Short-container-title:Parkinsonism & Related Disorders

Author:

Przytuła Filip^ORCID,Kasprzak Jakub,Dulski Jarosław^ORCID,Koziorowski Dariusz,Kwaśniak-Butowska Magdalena,Sołtan Witold,Roszmann Anna,Śmiłowska Katarzyna,Schinwelski Michał,Sławek Jarosław

Publisher

Elsevier BV

Subject

Neurology (clinical),Geriatrics and Gerontology,Neurology

Reference28 articles.

1. Update to living WHO guideline on drugs for covid-19;BMJ,2022

2. What can Parkinson's disease teach us about COVID-19?;Tipton;Neurol. Neurochir. Pol.,2020

3. Potential for the repurposing of adamantane antivirals for COVID-19;Butterworth;Drugs R,2021

4. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment;Smieszek;Int. J. Antimicrob. Agents,2020

5. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2;Cortés-Borra;Pharmacol. Rep.,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis of neuropsychic complications of new coronavirus infection;Medical academic journal;2024-05-23

2. SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now;Biomedicines;2023-09-13

3. Incidence and characteristics of post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines;Neurologia i Neurochirurgia Polska;2023-02-28